Study of Cognitive Changes in Women 60 and Older with Breast Cancer Receiving Systemic Therapy

What this Trial Is About

Researchers are investigating how systemic therapy affects cognitive function in older women with breast cancer. This study focuses on women aged 60 and older, aiming to evaluate changes in attention, processing speed, executive function, learning, memory, and overall cognition over five years. The study also explores connections between cognitive decline and quality of life, and examines how genetic factors, inflammation, sleep, and physical health influence cognitive outcomes in this population. The study involves two groups women aged 60 and above newly diagnosed with breast adenocarcinoma stages 0-3 or planning neoadjuvant therapy and a control group of women without breast cancer. Participants undergo baseline neuropsychological testing before any systemic treatment or at enrollment for controls. Follow-up assessments, including physical tests, blood or saliva samples for genetic and biomarker analysis, sleep monitoring, and optional neuroimaging, take place annually for up to five years. Participants complete questionnaires about cognitive function, sleep, quality of life, and daily activities. Physical performance tests like grip strength and walking speed are conducted. Clinical data are collected from medical records. The primary outcomes measure changes in cognitive domains annually. Secondary outcomes include quality of life changes, cancer-related symptoms, aging biomarkers, and sleep patterns. The study lasts up to five years with ongoing evaluations to understand how systemic therapy impacts cognition and overall well-being in older breast cancer patients.

Older Breast Cancer Patients: Risk for Cognitive Decline